Skip to main content
OpenTrials

Clinical trial condition

Neuroendocrine Tumors

Explore clinical trials studying Neuroendocrine Tumors. Study availability and eligibility vary by location and protocol.

2,773 public trials 498 recruiting studies
Refine in advanced search Browse all conditions

Neuroendocrine Tumors trial results

Completed

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

NCT04148937

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Cancer, +52 more
Locations
  • Sarah Cannon Research Institute at HealthOne Denver, Colorado, United States
  • Florida Cancer Specialists ORLANDO/DDU Lake Mary, Florida, United States
  • START Midwest Grand Rapids, Michigan, United States
  • Washington University Medical School St Louis, Missouri, United States
View Trial Details
Completed

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

NCT03329950

Conditions
Adenocarcinoma, Adnexal Diseases, Bile Duct Diseases, +120 more
Locations
  • HonorHealth Research Insititute Scottsdale, Arizona, United States
  • Northside Hospital, Inc. Atlanta, Georgia, United States
  • Georgia Cancer Center at Augusta University Augusta, Georgia, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists Omaha, Nebraska, United States
View Trial Details
Completed

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

NCT02155647

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Merkel Cell, +13 more
Locations
  • UCLA Medical Center Los Angeles, California, United States
  • The Angeles Clinic and Research Institute - West LA Los Angeles, California, United States
  • University of Colorado Aurora, Colorado, United States
  • H. Lee Moffitt Cancer Center and Research Institute, Inc Tampa, Florida, United States
View all 61 locations
View Trial Details
Completed

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

NCT02678741

Conditions
Melanoma, Metastatic Melanoma, Neoplasms, +10 more
Locations
  • University of Alabama Birmingham Comprehensive Cancer Center Birmingham, Alabama, United States
  • John Wayne Cancer Institute/Providence Saint John's Health Center Santa Monica, California, United States
  • Mount Sinai Comprehensive Cancer Center Miami Beach, Florida, United States
  • Northside Hospital Atlanta, Georgia, United States
View Trial Details

Related conditions